{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
Source:
ANDA074612
(1999)
Source URL:
First approved in 1999
Source:
ANDA074612
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(1999)
Source URL:
First approved in 1999
Source:
21 CFR 352
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Possibly Marketed Outside US
Source:
Clearasil
Source URL:
First approved in 1999
Source:
21 CFR 352
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Status:
Possibly Marketed Outside US
Source:
21 CFR 333D
(2003)
Source URL:
First approved in 1999
Source:
21 CFR 333D
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(1999)
Source URL:
First approved in 1999
Source:
21 CFR 352
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
First approved in 1999
Source:
Dermal-Soothe by Vetoquinol USA, Inc.
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Myristalkonium is used as spermicide in vaginal contraceptives. It has antiseptic properties also. Breastfeeding women might use it because it does not pass into maternal milk. Absorbed only on the surface of the walls of the vagina and then return to normal physiological droppings or eliminates simple washing with water. Adverse effects are: burning, itch, contact dermatitis. Any drug, introduced into the vagina, can inactivate the local spermicidal action of Myristalkonium.
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2020)
Source URL:
First approved in 1999
Source:
Seba-Hex by Vetoquinol USA, Inc.
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
BLA103665
(1999)
Source URL:
First approved in 1999
Source:
BLA103665
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
21 CFR 358
(1999)
Source URL:
First approved in 1999
Source:
21 CFR 358
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
First approved in 1999
Source:
NADA141152
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Selamectin (trade name Revolution, Stronghold) is a broad-spectrum endectocide. It is used in dogs and cats for treatment, control and prevention against fleas, heartworms, ear mites, ticks and other parasites. Selamectin is not approved for human use. It is a a semi-synthetic compound of the avermectin class, a macrocyclic lactone.